Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Lancet Oncol. 2016 Mar 11;17(4):452–463. doi: 10.1016/S1470-2045(15)00614-2

Figure 2. Best percentage change from baseline in tumour volume.

Figure 2

Figure 2

Figure 2

Figure 2

(A) ALKi-naïve patients (n=77) and (B) ALKi-pretreated patients (n=151); upper dotted line indicates threshold for disease progression (PD), lower dotted line represents the threshold of a 30% decrease from baseline (patients with a PR or CR will meet or exceed this threshold) and where the changes fall between the two dotted lines, SD is defined; *n=number of patients with measurable disease at baseline and at least one valid post baseline tumour assessment. (C) Duration of response in all patients with ALK-rearranged NSCLC who responded to ceritinib treatment (N=152) (D) Progression-free survival in all patients with ALK-rearranged NSCLC (N=246)

ALK=anaplastic lymphoma kinase. CR=complete response. PR=partial response. SD=stable disease.